License Revenue was Keros Therapeutics’s largest product and service line in fiscal 2025, bringing in $205.36M of $243.86M (84%).
| Product and Service | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| License Revenue | $18.00M | — | $3.00M | $205.36M | |
| Service Revenue | — | — | — | $38.51M | |
| Service & Other Revenue | — | $151.00K | $550.00K | — | |
| Total | $18.00M | $151.00K | $3.55M | $243.86M |
Keros Therapeutics brought in $243.86M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Keros Therapeutics regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $3.55M. License Revenue was the largest at $205.36M (84.2%), ahead of Service Revenue at $38.51M (15.8%).
Keros Therapeutics began breaking out Service Revenue in fiscal 2025, when it brought in $38.51M. Keros Therapeutics stopped reporting Service & Other Revenue as a separate line after fiscal 2024, when it brought in $550.00K.
Keros Therapeutics (KROS) reports its revenue by product and service. In fiscal 2025, License Revenue was its largest product and service line, bringing in $205.36M (84.2% of the total), followed by Service Revenue at $38.51M (15.8%).
License Revenue was Keros Therapeutics' largest product and service line in fiscal 2025, bringing in $205.36M, or 84.2% of the $243.86M total across its two product and service lines.
Every figure comes from Keros Therapeutics' annual financial filings, as reported. Each line keeps the name Keros Therapeutics gives it, and years follow its fiscal calendar.
Keros Therapeutics' revenue by product and service goes back to fiscal 2021, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.